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Clinical features of a novel TIMP-3 mutation
causing Sorsby’s fundus dystrophy: implications
for disease mechanism
Michael Clarke, Keith W Mitchell, Judith Goodship, Sharon McDonnell,
Michael D Barker, Ian D GriYths, Norman McKie
Abstract
Aims—To describe the phenotype in three
family members aVected by a novel muta-
tion in the gene coding for the enzyme tis-
sue inhibitor of metalloproteinase-3
(TIMP-3).
Methods—Three members of the same
family were seen with a history of nyctalo-
pia and visual loss due to maculopathy.
Clinical features were consistent with
Sorsby’s fundus dystrophy. Exon 5 of the
gene coding for TIMP-3 was amplified by
the polymerase chain reaction, single
strand conformation polymorphism
analysis undertaken and exon 5 amplicons
were directly sequenced.
Results—Onset of symptoms was in the
third to fourth decade. Five of six eyes had
geographic macular atrophy rather than
neovascularisation as a cause for central
visual loss. Peripheral retinal pigmentary
disturbances were present. Scotopic ERGs
were abnormal in all three. Mutation
analysis showed a G→T transversion in all
three resulting in a premature termina-
tion codon, E139X, deleting most of the
carboxy terminal domain of TIMP-3.
Conclusions—The patients described had
a form of Sorsby’s fundus dystrophy
which fell at the severe end of the
spectrum of this disease. Postulated dis-
ease mechanisms include deposition of
dimerised TIMP-3 protein.
(Br J Ophthalmol 2001;85:1429–1431)
In 1949, Sorsby and Mason described five
families with a dominantly inherited central
retinal dystrophy leading to visual loss in the
fifth decade.1 The involvement of the periph-
eral retina in addition led to the condition
being named Sorsby’s fundus dystrophy
(SFD).2
SFD is of interest because the neovascular
macular lesion resembles that seen in age
related maculopathy due to subretinal neovas-
cularisation. Age related maculopathy is the
commonest cause of blindness in the western
world, and 10% of age related maculopathy is
due to subretinal neovascularisation.3
The discovery of mutations in the tissue
inhibitor of metalloproteinase-3 (TIMP-3)
gene in some families labelled as SFD
indicated that it was truly a separate disorder.4
Five mutations have been described to date, all
clustered in exon 5 and all single base substitu-
tions resulting in novel cysteine residues.4–6 A
Japanese family has been described with a
splice site mutation.7 All UK families had been
thought to have a common S181C mutation,
indicating a founder eVect8; however, we have
recently identified a family from the north east
of England with a previously undescribed
mutation causing a premature termination
codon and loss of the terminal 49 amino acids
of the protein.
Case descriptions
Patient III:2 presented with loss of central acu-
ity and night blindness at the age of 25. When
examined at the age of 72, the visual acuity in
each eye was hand movements only. There was
complete chorioretinal atrophy at each macula.
The retinal vessels were thinned and there was
pigmentation in the retinal periphery.
Rheumatological and general medical exam-
ination was normal apart from varicose veins
and mild discomfort in the hip and shoulder.
Renal function was normal.
Patient IV:4 presented aged 36 years with
blurred vision in the left eye. Visual acuity was
6/6 in the right eye and 6/60 in the left eye.
Examination of the left retina showed a
disciform scar. Drusen were present at the
right macula and there was peripheral retinal
pigmentation in both eyes. An electroretino-
gram showed photopic responses which were
within normal limits (although those from the
right eye were larger than from the left), but
scotopic responses were subnormal in both
eyes.An electro-oculogram had an Arden ratio
of 1.2 indicating retinal pigment epithelial dys-
function. At age 44 years the vision in the right
eye deteriorated over a period of several weeks
to 6/24. Examination showed a flat pigmentary
disturbance which did not leak on fluorescein
angiography (Fig 1).
Rheumatological and general medical exam-
ination was normal. Creatinine was 116 µmol/l
(normal less than 110), urea 5.2 mmol/l.
Patient IV:10 presented aged 37 with a 4
year history of nyctalopia predominantly af-
fecting central vision. Her own mother, the sis-
ter of case 1 had died in early middle age with-
out developing visual symptoms.
Visual acuity at presentation was 6/18 right
and 6/9 left with a low myopic correction. Reti-
nal examination was within normal limits apart
from peripheral choroidal hypopigmentation.
An electroretinogram showed normal photopic
responses but on dark adaptation the scotopic
b waves were broad and of low amplitude and
did not increase on prolonged adaptation, indi-
cating a defect in the rod photoreceptor system
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(Fig 2). Pattern electroretinograms were totally
extinguished in right eye, and just recordable in
the left.
A fluorescein angiogram showed paramacu-
lar defects of the retinal pigment epithelium.
Subsequently, geographic atrophy of the retinal
pigment epithelium and choroid at the macula
led to loss of central vision 17 years after pres-
entation.
Rheumatological and general medical exam-
ination was normal apart from mild varicose
veins.
DNA analysis
Blood was obtained from the three aVected
individuals and a normal control, and polymer-
ase chain reaction, restriction digest, single
strand conformation polymorphism analysis,
and DNA sequencing were carried out for
exon 5 of the TIMP-3 gene as described previ-
ously.9 Direct DNA sequencing showed a
G→T transversion in one allele in the first base
of codon 139 in the three aVected individuals
resulting in a TAG termination codon replac-
ing the normal GAG glutamic acid codon
(E139X). They did not have the S181C muta-
tion seen in other British families.
Discussion
Sorsby’s fundus dystrophy is known to be asso-
ciated with mutations in the gene for TIMP-3.4
There are four very similar tissue inhibitors of
metalloproteinases (TIMPs)10 comprising a
gene family with 12 highly conserved cysteine
residues which form six disulphide bridges
essential for correct protein folding and func-
tion. TIMPs consist of two domains each stabi-
lised by three disulphide bonds, an amino
terminal inhibitory domain, through which they
bind to an active matrix metalloproteinase, and
a carboxy terminal domain, which is involved in
interactions with proform matrix metalloprotei-
nases. The positions of the disulphide bonds
have been assigned in TIMP-1 and by compari-
son of the two molecules it is likely that the
disulphide bonds in the carboxy terminus of
TIMP-3 are between residues 122–169, 127–
132, and 140–161.11 Immunohistochemistry of
human eyes shows TIMP-3 specific staining in
Bruch’s membrane, particularly in the basement
membranes of retinal pigment epithelial and
endothelial cells.12 Overexpression of TIMP-3 in
transfected rat retinal pigment epithelium inhib-
its experimental choroidal neovascularisation.13
The five mutations previously identified in
patients with Sorsby’s fundus dystrophy are in
the carboxy terminal domain and all lead to
cysteine substitutions (S156C, G166C,
G167C, Y168C, S181C). It is likely that these
cysteine substitutions lead to abnormal disul-
phide bonding and thus alter the protein’s con-
formation. The novel mutation we have identi-
fied deletes most of the carboxy terminal
domain and will be expected to alter its struc-
ture markedly as only one of the disulphide
bridges could form. This mutation leaves the
C-terminal region in TIMP-3 with an un-
paired cysteine residue by deleting three of the
six cysteines and so may also lead to altered
protein conformation.
Ocular features in pedigrees with SFD have
shown considerable interfamilial, intrafamilial,
and even intraindividual variations with regard
to age of onset, speed of progression, involve-
ment of the second eye, neovascularisation,
and peripheral retinal involvement.14
Only one member of our family had a disci-
form scar in one eye. In families with the
S181C, Y168C, and S156C mutations, neo-
vascularisation is a prominent feature.5 15 Peri-
pheral visual field loss is seen in both the
S181C and E139X mutations, although night
blindness tended to precede visual loss in indi-
viduals with the E139X mutation. A Japanese
family has been described with a splice site
mutation which causes a later onset (seventh
decade) disease with preserved peripheral reti-
nal function.7
The mechanism by which mutations in
TIMP-3 give rise to retinal disease is not
Figure 1 Patient IV:4. (A) Right fundus. (B) Right fundus fluorescein angiogram, transit phase.
Figure 2 Photopic flash and flicker; and scotopic flash full field ERGs of patient IV:10
and age matched control.
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known, but is unlikely to be due to loss of
TIMP-3 function as expression studies have
shown all known disease causing mutants to be
functional metalloproteinase inhibitors.9 An
eye from a patient with SFD has been studied
histologically, and has been shown to have an
eosinophilic deposit at the level of Bruch’s
membrane.2 This deposit stains for TIMP-316
and may represent an insoluble dimerised form
of the enzyme produced by abnormal disul-
phide bond formation by the mutated protein
which may be associated with elastin.17 We
have previously demonstrated dimerisation of
the protein product of S181C, S156C,G166C,
and E139X.9 One possible mechanism for reti-
nal disease may therefore be impairment of the
nutrition and metabolism of the outer retina
because of abnormal deposition of dimerised
TIMP-3 in Bruch’s membrane. This is sup-
ported by the finding of reversal of night blind-
ness in SFD using high dose vitamin A supple-
mentation.18 TIMP-3 is known to express
apoptotic properties when overexpressed in
vitro,19 and an altenative mechanism, particu-
larly for the patients’ atrophic maculopathy,
could be apoptosis of photoreceptor and
retinal pigment epithelial cells induced by
accumulation of dimerised TIMP-3.
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